Last updated on February 2018

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis


Brief description of study

This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF), or who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del).

Clinical Study Identifier: NCT02951195

Contact Investigators or Research Sites near you

Start Over

Birmingham, AL United States

La Jolla, CA United States

Los Angeles, CA United States

Orlando, FL United States

Chicago, IL United States

Peoria, IL United States

Saint Louis, MO United States

Chapel Hill, NC United States

Akron, OH United States

Cleveland, OH United States

Portland, OR United States

Philadelphia, PA United States

Charleston, SC United States

Fort Worth, TX United States

Houston, TX United States

Madison, WI United States